Agilent touts SomaLogic’s research tool

BOULDER – Agilent Technologies Inc. (NYSE: A) will help Boulder-based biotech SomaLogic Inc. expand access to SomaLogic’s protein biomarker discovery platform used by researchers.

Terms of the agreement were not disclosed.

The companies will place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers.

Although the SOMAscan assay already is available to researchers directly from SomaLogic as a service, this planned rollout is aimed at meeting the growing demand for access to SomaLogic’s multiplexed, cost-effective proteomic analyses.

“We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere,´ said Larry Gold, chairman and chief executive of SomaLogic.

on Facebook on LinkedIn